ORYZON Reports Results for Quarter Ended September 30, 2020 and Provides Corporate Update

NASDAQ Market News

NEXT STORY
Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020
PREV STORY
Orphan Drugs Market to Reach USD 340.84 Billion with 10.5% CAGR by 2027; Increasing Number of Regulatory Approvals will Contribute to Market Growth, says Fortune Business Insights™
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Inventiva files registration statement for proposed initial public offering in the United States

author_avatar
NASDAQ Market News

Oasmia presenterar positiva effekt- och säkerhetsdata för Doxophos Vet i studie med tidigare obehandlade hundar med lymfom

Data avseende övergripande tumörrespons (s.k. overall response rate) i (RXE1) fas II-studien som utfördes ...

author_avatar
NASDAQ Market News

EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD

author_avatar
NASDAQ Market News